Genocea Biosciences (GNCA) Misses Q4 EPS by 11c

Genocea Biosciences (NASDAQ: GNCA) reported Q4 EPS of ($0.56), $0.11 worse than the analyst estimate of ($0.45). Revenue for the quarter came in at $0, versus $0 reported last year.

Cash, cash equivalents and investments as of December 31, 2016 were $63.4 million compared to $75.5 million as of September 30, 2016.

For earnings history and earnings-related data on Genocea Biosciences (GNCA) click here.

You May Also Be Interested In

• LeonaBio (LONA) Price Target Cut to $17 by Citizens Amid Pipeline Development
• Palo Alto Networks (PANW) PT Raised to $400 at TD Cowen
• Celcuity (CELC) Reiterates at Market Outperform by Citizens Ahead of Upcoming Launch